世界のプロテオミクス市場予測(~2026年):製品別(分光法、クロマトグラフィー、電気泳動、X線結晶構造解析)、試薬別、サービス別(コアプロテオミクス、バイオインフォマティクス)、用途別(診断、創薬)、エンドユーザー別(病院、ラボ、バイオ医薬品)

◆英語タイトル:Proteomics Market by Product (Spectroscopy, Chromatography, Electrophoresis, X-ray Crystallography), Reagent, Service (Core Proteomics, Bioinformatics), Application (Diagnostic, Drug Discovery), End User (Hospital, Labs, Biopharma) - Global Forecast to 2026
◆商品コード:BT2341
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年3月9日
◆ページ数:290
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥569,250見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥764,750見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥937,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は世界のプロテオミクス市場規模が2021年259億ドルから2026年559億ドルまで、年平均16.6%成長すると予想しています。本市場調査資料では、プロテオミクスの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、計装技術別(分光法、クロマトグラフィー、電気泳動、タンパク質マイクロアレイ、X線結晶)分析、試薬別(イムノアッセイ試薬、分光試薬、クロマトグラフィー試薬、タンパク質マイクロアレイ試薬、X線結晶学試薬)分析、サービス・ソフトウェア別(コアプロテオミクスサービス、バイオインフォマティクスソフトウェア・サービス)分析、用途別(臨床診断、創薬、その他)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のプロテオミクス市場規模:計装技術別(分光法、クロマトグラフィー、電気泳動、タンパク質マイクロアレイ、X線結晶)
・世界のプロテオミクス市場規模:試薬別(イムノアッセイ試薬、分光試薬、クロマトグラフィー試薬、タンパク質マイクロアレイ試薬、X線結晶学試薬)
・世界のプロテオミクス市場規模:サービス・ソフトウェア別(コアプロテオミクスサービス、バイオインフォマティクスソフトウェア・サービス)
・世界のプロテオミクス市場規模:用途別(臨床診断、創薬、その他)
・世界のプロテオミクス市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global proteomics market is projected to reach USD 55.9 billion by 2026 from USD 25.9 billion in 2021, at a CAGR of 16.6% during the forecast period.”
An increase in the research activity, especially in the area of personalized medicine and drug discovery, is the primary growth driver for this market. In addition, the increasing R&D expenditure by pharmaceutical and biotechnology companies, increasing government funding, and technological advancements are also propelling the market growth.

“The protein fractionation segment accounted for the highest growth rate in the proteomics market, by instrumentation technology, during the forecast period.”
Based on instrumentation technology, the proteomics market is segmented into spectroscopy, chromatography, electrophoresis, protein microarrays, X-ray crystallography, surface plasmon resonance (SPR), and protein fractionation. During the forecasted period, protein fractionation segment is expected to grow at a highest CAGR in the global proteomic market. However, the ability of spectroscopy to quantify the complex structure of proteins on a large scale, providing quality results, and the capability of integration with other technologies for protein quantification make spectroscopy an indispensable tool in proteomics.

“Academic research laboratoires segment accounted for the highest CAGR”
Based on end users, the proteomics market is segmented into hospitals, clinical laboratories, pharmaceutical companies, academic research laboratories, and other end users. During the forecasted period, the academic research laboratories segment is expected to register the highest CAGR in the global proteomics market.However, pharmcautical companies segment accounted for the largest share in 2020. The large share of this segment can be attributed to the increasing research funding for genomics and proteomics research and the increasing outsourcing of research activities to various pharmaceutical companies with in-house CRO services.

“Asia Pacific: The fastest-growing region proteomics market.”
The Asia Pacific market is expected to witness the highest growth during the forecast period, primarily due to the increasing investments by governments and industries, growing biotechnology research, and rising awareness of personalized therapeutics.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35%
• By Designation: C-level – 30%, D-level – 20%, and Others – 50%
• By Region: North America – 36%, Europe – 25%, Asia Pacific – 27%, Latin America – 9%, and Middle East and Africa – 3%.

List of companies profiled in the report:
• Thermo Fisher Scientific Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (US)
• Bruker Corporation (US)
• Danaher Corporation (US)
• GE Healthcare (US)
• Luminex Corporation (US)
• PerkinElmer Inc. (US)
• Waters Corporation (US)
• Illumina, Inc. (US)
• Eurofins Scientific (Luxembourg)
• QIAGEN Bioinformatics (Netherlands)
• Creative Proteomics (US)
• Promega Corporation (US)
• Sengenics (Singapore)
• Biomax Informatics AG (Germany)
• MS Bioworks LLC (US)
• WuXi NextCODE (China)
• Fios Genomics Ltd. (UK)
• GENEWIZ (US)
• Biognosys AG (Switzerland)
• Bioproximity (Switzerland)
• MRM Proteomics Inc. (Canada)
• Integrated Proteomics Applications (US)
• Poochon Scientific, LLC (US)
• Proteome Factory AG (Germany)
• VProteomics (India)
• HORIBA, Ltd. (Japan)
• Applied Biomics, Inc. (US).

Research Coverage:
This report provides a detailed picture of the global proteomics market. It aims at estimating the size and future growth potential of the market across different segments, such as instrumentation technology, reagent, software and service, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall proteomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, challenges, and trends.

【レポートの目次】

1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
FIGURE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY 33
1.2.1 MARKETS COVERED 34
FIGURE 2 PROTEOMICS MARKET SEGMENTATION 34
1.2.2 YEARS CONSIDERED FOR THE STUDY 35
1.3 CURRENCY 35
1.4 STAKEHOLDERS 35
1.5 LIMITATIONS 35
1.6 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 3 RESEARCH DESIGN 37
2.1.1 SECONDARY RESEARCH 38
2.1.1.1 Key data from secondary sources 38
2.1.2 PRIMARY DATA 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 40
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION 41
FIGURE 6 BOTTOM-UP APPROACH: SEGMENTAL REVENUE ESTIMATION 41
2.2.2 TOP-DOWN APPROACH 42
FIGURE 7 PROTEOMICS MARKET: TOP-DOWN APPROACH 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 43
FIGURE 8 DATA TRIANGULATION METHODOLOGY 43
2.4 ASSUMPTIONS FOR THE STUDY 44
3 EXECUTIVE SUMMARY 45
FIGURE 9 PROTEOMICS MARKET, BY INSTRUMENTATION TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 45
FIGURE 10 PROTEOMICS MARKET, BY REAGENT, 2021 VS. 2026 (USD MILLION) 46
FIGURE 11 PROTEOMICS MARKET, BY SERVICE & SOFTWARE,
2021 VS. 2026 (USD MILLION) 46
FIGURE 12 PROTEOMICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION) 47
FIGURE 13 PROTEOMICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 47
FIGURE 14 PROTEOMICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 48
4 PREMIUM INSIGHTS 49
4.1 PROTEOMICS MARKET OVERVIEW 49
FIGURE 15 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 49
4.2 SPECTROSCOPY MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 50
FIGURE 16 MASS SPECTROSCOPY SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026 50
4.3 ELECTROPHORESIS MARKET SHARE, BY TYPE, 2021 VS. 2026 50
FIGURE 17 GEL ELECTROPHORESIS SEGMENT WILL ACCOUNT FOR THE LARGEST MARKET SHARE IN 2021 50
4.4 PROTEOMICS MARKET, BY REGION (2021−2026) 51
FIGURE 18 ASIA PACIFIC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 19 PROTEOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 MARKET DRIVERS 53
5.2.1.1 Increasing demand for personalized medicine 53
FIGURE 20 NUMBER OF PERSONALIZED MEDICINES IN THE MARKET, 2008–2020 53
5.2.1.2 Rising prevalence of cancer and associated genetic disorders 54
TABLE 1 CANCER INCIDENCE AND MORTALITY, BY REGION, 2012–2035 54
5.2.1.3 Proteomics bridges the gap between genomics and biochemistry 55
5.2.1.4 Increasing pharmaceutical and biotechnology R&D expenditure 55
FIGURE 21 R&D EXPENDITURE BY PHRMA MEMBER COMPANIES,
2001–2019 (USD BILLION) 56
TABLE 2 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2018 56
TABLE 3 FUNDING FOR NIH INNOVATION PROJECTS UNDER THE 21ST CENTURY CURES ACT, 2017–2026 57
5.2.1.5 Technological advancements 57
5.2.2 MARKET RESTRAINTS 58
5.2.2.1 High cost of instruments 58
5.2.3 MARKET OPPORTUNITIES 58
5.2.3.1 Growing prominence of nanoproteomics 58
5.2.3.2 Development of personalized proteomics for precision health 59
5.2.3.3 High growth opportunities in emerging countries 59
5.2.4 MARKET CHALLENGES 60
5.2.4.1 Data management in proteomics research 60
5.2.4.2 Low biomarker discovery-to-approval ratio 61
5.3 IMPACT OF COVID-19 ON THE PROTEOMICS MARKET 61
5.4 PATENT ANALYSIS 62
FIGURE 22 PROTEOMICS MARKET: PATENT ANALYSIS 62
5.5 ECOSYSTEM ANALYSIS 63
5.6 VALUE CHAIN ANALYSIS 63
FIGURE 23 PROTEOMICS MARKET: VALUE CHAIN ANALYSIS 64
5.6.1 PROTEOMICS MARKET: VALUE CHAIN ANALYSIS, BY ORGANIZATION 64
5.6.2 PROTEOMICS MARKET: VALUE CHAIN ANALYSIS, BY MAJOR SPECIALIZATION 65
5.7 SUPPLY CHAIN ANALYSIS 66
FIGURE 24 PROTEOMICS MARKET: SUPPLY CHAIN ANALYSIS 66
5.8 PORTER’S FIVE FORCES ANALYSIS 67
FIGURE 25 PROTEOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 67
5.8.1 THREAT OF NEW ENTRANTS 67
5.8.2 THREAT OF SUBSTITUTES 67
5.8.3 BARGAINING POWER OF BUYERS 67
5.8.4 BARGAINING POWER OF SUPPLIERS 68
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 68
5.9 PESTEL ANALYSIS 69
FIGURE 26 PROTEOMICS MARKET: PESTEL ANALYSIS 69
5.10 TRADE ANALYSIS 70
5.10.1 TRADE ANALYSIS FOR ELECTROPHORESIS & CHROMATOGRAPHY INSTRUMENTS 70
TABLE 4 IMPORT DATA FOR ELECTROPHORESIS AND CHROMATOGRAPHY INSTRUMENTS, BY COUNTRY, 2016-2020 (USD MILLION) 70
5.10.2 TRADE ANALYSIS FOR SPECTROSCOPY INSTRUMENTS 70
TABLE 5 IMPORT DATA FOR SPECTROSCOPY INSTRUMENTS, BY COUNTRY, 2016-2020 (USD MILLION) 70
5.11 REGULATORY GUIDELINES 71
5.11.1 NORTH AMERICA 71
5.11.2 EUROPE 71
5.11.3 EMERGING MARKETS 71
6 PROTEOMICS MARKET, BY INSTRUMENTATION TECHNOLOGY 72
6.1 INTRODUCTION 73
6.1.1 PRICING ANALYSIS 73
TABLE 6 AVERAGE SELLING PRICES OF PRODUCTS AND SERVICES, 2021 (USD) 73
TABLE 7 PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 73
TABLE 8 PROTEOMICS INSTRUMENTATION TECHNOLOGY MARKET, BY TYPE,
2019–2026 (USD MILLION) 74
TABLE 9 PROTEOMICS INSTRUMENTATION TECHNOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 74
6.2 SPECTROSCOPY 75
TABLE 10 SPECTROSCOPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 75
TABLE 11 SPECTROSCOPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 76
6.2.1 MASS SPECTROSCOPY 76
6.2.1.1 The ability of MS to identify small amounts of protein from increasingly complex mixtures is a major factor driving its use in proteomics 76
TABLE 12 MASS SPECTROSCOPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 78
6.2.2 NMR SPECTROSCOPY 78
6.2.2.1 NMR experiments are used to evaluate the physical, chemical, electronic, and structural information of proteins 78
TABLE 13 NMR SPECTROSCOPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 79
6.2.3 CD SPECTROSCOPY 79
6.2.3.1 CD spectroscopy is used to examine changes in secondary structures of proteins in response to environmental conditions 79
TABLE 14 CD SPECTROSCOPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 80
6.3 CHROMATOGRAPHY 81
TABLE 15 CHROMATOGRAPHY MARKET, BY TYPE, 2019–2026 (USD MILLION) 81
TABLE 16 CHROMATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 82
6.3.1 HPLC 82
6.3.1.1 The two types of HPLC systems commonly available in the market are split-flow systems and non-split-flow systems 82
TABLE 17 HPLC MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83
6.3.2 ION CHROMATOGRAPHY 84
6.3.2.1 Ion chromatography is the most commonly used chromatographic method for separating proteins 84
TABLE 18 ION CHROMATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 84
6.3.3 AFFINITY CHROMATOGRAPHY 85
6.3.3.1 Affinity chromatography is used for the isolation of proteins based on the interaction between target proteins and specific immobilized ligands 85
TABLE 19 AFFINITY CHROMATOGRAPHY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 86
6.3.4 SUPERCRITICAL FLUID CHROMATOGRAPHY 86
6.3.4.1 SFC is used for the separation and analysis of integral membrane proteins and hydrophobic peptides 86
TABLE 20 SUPERCRITICAL FLUID CHROMATOGRAPHY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 87
6.4 ELECTROPHORESIS 87
TABLE 21 ELECTROPHORESIS MARKET, BY TYPE, 2019–2026 (USD MILLION) 88
TABLE 22 ELECTROPHORESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88
6.4.1 GEL ELECTROPHORESIS 89
6.4.1.1 The most common use of gel electrophoresis is the qualitative analysis of a complex mixture of proteins 89
TABLE 23 GEL ELECTROPHORESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 89
6.4.2 CAPILLARY ELECTROPHORESIS 90
6.4.2.1 CE coupled with MS is used to assess the structure and identity of individual proteins 90
TABLE 24 CAPILLARY ELECTROPHORESIS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 91
6.5 PROTEIN MICROARRAYS 91
TABLE 25 PROTEIN MICROARRAYS MARKET, BY TYPE, 2019–2026 (USD MILLION) 92
TABLE 26 PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 92
6.5.1 BIOCHIPS 93
TABLE 27 BIOCHIPS MARKET, BY TYPE, 2019–2026 (USD MILLION) 93
TABLE 28 BIOCHIPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
6.5.1.1 Lab-on-chips 94
6.5.1.1.1 LOC is one of the fastest-growing areas of microfabrication and nanotechnology development 94
TABLE 29 LAB-ON-CHIPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
6.5.1.2 Protein chips 95
6.5.1.2.1 Protein chips are used to study protein interactions 95
TABLE 30 PROTEIN CHIPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 96
6.5.2 MICROARRAY INSTRUMENTS 96
TABLE 31 MICROARRAY INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 97
TABLE 32 MICROARRAY INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 97
6.5.2.1 Integrated systems 98
6.5.2.1.1 Integrated systems can carry out the entire procedure of protein analysis without any intermediate steps 98
TABLE 33 INTEGRATED SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 98
6.5.2.2 Microarray scanners 99
6.5.2.2.1 Microarray scanners find applications in the data analysis of proteins, tissues, and cells 99
TABLE 34 MICROARRAY SCANNERS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 99
6.5.2.3 Arrayers 100
6.5.2.3.1 Technological advancements have made microarray spotters ideal for large-scale arraying projects 100
TABLE 35 ARRAYERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 100
6.6 X-RAY CRYSTALLOGRAPHY 101
6.6.1 X-RAY CRYSTALLOGRAPHY HELPS IN THE MEASUREMENT OF THE 3D DENSITY DISTRIBUTION OF ELECTRONS IN A CRYSTALLIZED PROTEIN 101
TABLE 36 X-RAY CRYSTALLOGRAPHY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 102
6.7 SURFACE PLASMON RESONANCE 102
6.7.1 SPR IMAGING HELPS MONITOR A RANGE OF MOLECULAR INTERACTIONS 102
TABLE 37 SURFACE PLASMON RESONANCE MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 103
6.8 PROTEIN FRACTIONATION 104
6.8.1 PROTEIN FRACTIONATION ENABLES THE EFFECTIVE SEPARATION OF THOUSANDS OF PROTEINS IN A COMPLEX MIXTURE 104
TABLE 38 PROTEIN FRACTIONATION MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 105

7 PROTEOMICS MARKET, BY REAGENT 106
7.1 INTRODUCTION 107
TABLE 39 PROTEOMICS REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 107
TABLE 40 PROTEOMICS REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
7.2 IMMUNOASSAY REAGENTS 108
7.2.1 IMMUNOASSAY REAGENTS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 108
TABLE 41 PROTEOMICS MARKET FOR IMMUNOASSAY REAGENTS, BY COUNTRY,
2019–2026 (USD MILLION) 109
7.3 SPECTROSCOPY REAGENTS 109
7.3.1 THE USE OF THESE REAGENTS IS INCREASING WITH THE RISING ADOPTION OF MS TECHNIQUES 109
TABLE 42 PROTEOMICS MARKET FOR SPECTROSCOPY REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 110
7.4 CHROMATOGRAPHY REAGENTS 110
7.4.1 INCREASING DEMAND FOR PROTEIN PURIFICATION IS EXPECTED TO DRIVE MARKET GROWTH 110
TABLE 43 PROTEOMICS MARKET FOR CHROMATOGRAPHY REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 111
7.5 PROTEIN MICROARRAY REAGENTS 111
7.5.1 THE USE OF THESE REAGENTS HAS INCREASED FOR ANALYZING PROTEIN INTERACTIONS 111
TABLE 44 PROTEOMICS MARKET FOR PROTEIN MICROARRAY REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 112
7.6 X-RAY CRYSTALLOGRAPHY REAGENTS 112
7.6.1 X-RAY CRYSTALLOGRAPHY PLAYS AN IMPORTANT ROLE IN PROTEIN STRUCTURE DETERMINATION 112
TABLE 45 PROTEOMICS MARKET FOR X-RAY CRYSTALLOGRAPHY REAGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 113
7.7 ELECTROPHORESIS REAGENTS 114
7.7.1 INCREASING DEMAND FOR 2D ELECTROPHORESIS IS DRIVING THE ADOPTION OF THESE REAGENTS 114
TABLE 46 PROTEOMICS MARKET FOR ELECTROPHORESIS REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 114
7.8 PROTEIN FRACTIONATION REAGENTS 115
7.8.1 INCREASING NEED FOR PROTEIN SEPARATION FROM COMPLEX MIXTURES IS DRIVING THE GROWTH OF THIS SEGMENT 115
TABLE 47 PROTEOMICS MARKET FOR PROTEIN FRACTIONATION REAGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 115
8 PROTEOMICS MARKET, BY SERVICE & SOFTWARE 116
8.1 INTRODUCTION 117
TABLE 48 PROTEOMICS SERVICES & SOFTWARE MARKET, BY TYPE,
2019–2026 (USD MILLION) 117
TABLE 49 PROTEOMICS SERVICES & SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 118
8.2 CORE PROTEOMICS SERVICES 118
TABLE 50 CORE PROTEOMICS SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 119
TABLE 51 CORE PROTEOMICS SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 119
8.2.1 PROTEIN IDENTIFICATION SERVICES 120
8.2.1.1 Protein identification services dominate the market 120
TABLE 52 PROTEIN IDENTIFICATION SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 121
8.2.2 PROTEIN CHARACTERIZATION SERVICES 121
8.2.2.1 Characterization studies play a vital role in studying complex protein structure, drug development, and PTMs 121
TABLE 53 PROTEIN CHARACTERIZATION SERVICES MARKET, BY COUNTRY,
2019 – 2026 (USD MILLION) 122
8.2.3 QUANTITATIVE PROTEOMICS SERVICES 123
8.2.3.1 Quantitative proteomics is critical for understanding protein expression and modifications 123
TABLE 54 QUANTITATIVE PROTEOMICS SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 124
8.2.4 PROTEIN PURIFICATION SERVICES 124
8.2.4.1 Protein purification aids in improving the overall proteome analysis 124
TABLE 55 PROTEIN PURIFICATION SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 125
8.2.5 PROTEIN SEPARATION SERVICES 126
8.2.5.1 Separation plays an important role in the characterization of large-sized proteomes 126
TABLE 56 PROTEIN SEPARATION SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 127
8.2.6 PROTEIN SEQUENCING SERVICES 127
8.2.6.1 Identification and characterization of PTMs is an important area of research that needs protein sequencing 127
TABLE 57 PROTEIN SEQUENCING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
8.2.7 CUSTOM ASSAY SERVICES 129
8.2.7.1 Custom assays are adopted to improve the validation or consistency of the protein analysis procedures 129
TABLE 58 CUSTOM ASSAY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 129
8.3 BIOINFORMATICS SOFTWARE & SERVICES 130
TABLE 59 BIOINFORMATICS SOFTWARE & SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 60 BIOINFORMATICS SOFTWARE & SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 131
8.3.1 BIOINFORMATICS SERVICES 131
8.3.1.1 Bioinformatics services will dominate the market in the forecast period 131
TABLE 61 BIOINFORMATICS SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 132
8.3.2 BIOINFORMATICS TOOLS 132
8.3.2.1 Need for data management makes bioinformatics tools an imperative part of proteomics 132
TABLE 62 BIOINFORMATICS TOOLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 133
8.3.3 BIOINFORMATICS DATABASES 134
8.3.3.1 Databases majorly contribute to storing proteomics data along with integrating other omics databases 134
TABLE 63 BIOINFORMATICS DATABASES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 135
9 PROTEOMICS MARKET, BY APPLICATION 136
9.1 INTRODUCTION 137
TABLE 64 PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 137
9.2 CLINICAL DIAGNOSTICS 137
TABLE 65 PROTEOMICS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 66 PROTEOMICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY,
2019–2026 (USD MILLION) 139
9.2.1 CANCER 139
9.2.1.1 Increasing number of research studies in cancer therapeutics to drive the market growth 139
TABLE 67 CLINICAL DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY,
2019–2026 (USD MILLION) 140
9.2.2 INFECTIOUS DISEASES 140
9.2.2.1 Increasing prevalence of infectious diseases to drive the market growth 140
TABLE 68 CLINICAL DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 141
9.2.3 DIABETES 141
9.2.3.1 High burden of diabetes to propel market growth 141
TABLE 69 CLINICAL DIAGNOSTICS MARKET FOR DIABETES, BY COUNTRY,
2019–2026 (USD MILLION) 142
9.2.4 NEUROLOGICAL DISORDERS 142
9.2.4.1 Rising prevalence of neurological disorders to support market growth 142
TABLE 70 CLINICAL DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 143
9.2.5 AUTOIMMUNE DISEASES 143
9.2.5.1 Increasing prevalence of autoimmune diseases to drive the market growth 143
TABLE 71 CLINICAL DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 144
9.2.6 CARDIOVASCULAR DISEASES 144
9.2.6.1 High burden of CVD has increased the focus on developing reliable diagnostic tools 144
TABLE 72 CLINICAL DIAGNOSTICS MARKET FOR CVD, BY COUNTRY,
2019–2026 (USD MILLION) 145
9.2.7 OTHER CLINICAL DIAGNOSTIC APPLICATIONS 145
TABLE 73 OTHER CLINICAL DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 146
9.3 DRUG DISCOVERY 147
TABLE 74 PROTEOMICS MARKET FOR DRUG DISCOVERY, BY TYPE,
2019–2026 (USD MILLION) 147
TABLE 75 PROTEOMICS MARKET FOR DRUG DISCOVERY, BY COUNTRY,
2019–2026 (USD MILLION) 148
9.3.1 TARGET DISCOVERY 148
9.3.1.1 Increasing demand for personalized medicine to support the growth of this market 148
TABLE 76 DRUG DISCOVERY MARKET FOR TARGET DISCOVERY, BY COUNTRY,
2019–2026 (USD MILLION) 149
9.3.2 LEAD IDENTIFICATION 150
9.3.2.1 Lead identification is the most revenue-generating process 150
TABLE 77 DRUG DISCOVERY MARKET FOR LEAD IDENTIFICATION, BY COUNTRY,
2019–2026 (USD MILLION) 150
9.3.3 LEAD OPTIMIZATION 151
9.3.3.1 Lead optimization requires state-of-the-art informatics systems to facilitate transparent presentation and analysis 151
TABLE 78 DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY,
2019–2026 (USD MILLION) 151
9.3.4 PRECLINICAL STUDIES 152
9.3.4.1 FDA requires researchers to use GLP during preclinical studies 152
TABLE 79 DRUG DISCOVERY MARKET FOR PRECLINICAL STUDIES, BY COUNTRY,
2019–2026 (USD MILLION) 152
9.4 OTHER APPLICATIONS 153
TABLE 80 DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2019–2026 (USD MILLION) 153
10 PROTEOMICS MARKET, BY END USER 154
10.1 INTRODUCTION 155
TABLE 81 PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 155
10.2 PHARMACEUTICAL COMPANIES 155
10.2.1 RISING FOCUS ON DRUG DISCOVERY TO DRIVE MARKET GROWTH 155
TABLE 82 PROTEOMICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 156
10.3 ACADEMIC RESEARCH LABORATORIES 157
10.3.1 INCREASING RESEARCH FUNDING FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH 157
TABLE 83 PROTEOMICS MARKET FOR ACADEMIC RESEARCH LABORATORIES,
BY COUNTRY, 2019–2026 (USD MILLION) 158
10.4 HOSPITALS 158
10.4.1 RISING ADOPTION OF PROTEOMICS FOR DISEASE DIAGNOSIS TO DRIVE MARKET GROWTH 158
TABLE 84 PROTEOMICS MARKET FOR HOSPITALS, BY COUNTRY,
2019–2026 (USD MILLION) 159
10.5 CLINICAL LABORATORIES 160
10.5.1 INCREASING OUTSOURCING OF DIAGNOSTICS TESTS BY HOSPITALS IS SUPPORTING THE GROWTH OF THIS END-USER SEGMENT 160
TABLE 85 PROTEOMICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY,
2019–2026 (USD MILLION) 160
10.6 OTHER END USERS 161
TABLE 86 PROTEOMICS MARKET FOR OTHER END USERS, BY COUNTRY,
2019–2026 (USD MILLION) 162
11 PROTEOMICS MARKET, BY REGION 163
11.1 INTRODUCTION 164
TABLE 87 PROTEOMICS MARKET, BY REGION, 2019–2026 (USD MILLION) 164
11.2 NORTH AMERICA 165
FIGURE 27 NORTH AMERICA: PROTEOMICS MARKET SNAPSHOT 166
TABLE 88 NORTH AMERICA: PROTEOMICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 166
TABLE 89 NORTH AMERICA: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 167
TABLE 90 NORTH AMERICA: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 167
TABLE 91 NORTH AMERICA: PROTEOMICS MARKET, BY END USER,
2019–2026 (USD MILLION) 167
11.2.1 US 168
11.2.1.1 The US dominates the North American proteomics market 168
TABLE 92 US: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 168
TABLE 93 US: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 169
TABLE 94 US: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 169
11.2.2 CANADA 169
11.2.2.1 Strong infrastructure and availability of funding for biomedical research will support market growth 169
TABLE 95 CANADA: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 170
TABLE 96 CANADA: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 170
TABLE 97 CANADA: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 171
11.3 EUROPE 171
TABLE 98 EUROPE: PROTEOMICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 172
TABLE 99 EUROPE: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 172
TABLE 100 EUROPE: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 173
TABLE 101 EUROPE: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 173

11.3.1 GERMANY 173
11.3.1.1 Germany is the largest market for proteomics in Europe 173
TABLE 102 GERMANY: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 174
TABLE 103 GERMANY: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 174
TABLE 104 GERMANY: PROTEOMICS MARKET, BY END USER,
2019–2026 (USD MILLION) 175
11.3.2 UK 175
11.3.2.1 The UK has seen a surge in the prevalence of cancer 175
TABLE 105 UK: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 176
TABLE 106 UK: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 176
TABLE 107 UK: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 176
11.3.3 FRANCE 177
11.3.3.1 Proteomics research in France is strongly supported by the government 177
TABLE 108 FRANCE: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 177
TABLE 109 FRANCE: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 177
TABLE 110 FRANCE: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 178
11.3.4 SWITZERLAND 178
11.3.4.1 Market growth is primarily driven by the well-established pharmaceutical & biotechnology industry in the country 178
TABLE 111 SWITZERLAND: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 179
TABLE 112 SWITZERLAND: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 179
TABLE 113 SWITZERLAND: PROTEOMICS MARKET, BY END USER,
2019–2026 (USD MILLION) 179
11.3.5 ITALY 180
11.3.5.1 Growth in this market is mainly driven by increasing life science R&D 180
TABLE 114 ITALY: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 180
TABLE 115 ITALY: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 181
TABLE 116 ITALY: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 181
11.3.6 SPAIN 181
11.3.6.1 Spain has a well-established network of research centers, universities, and hospitals 181
TABLE 117 SPAIN: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 182
TABLE 118 SPAIN: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 182
TABLE 119 SPAIN: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 182
11.3.7 REST OF EUROPE 183
TABLE 120 ROE: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 183
TABLE 121 ROE: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 184
TABLE 122 ROE: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 184
11.4 ASIA PACIFIC 184
FIGURE 28 ASIA PACIFIC: PROTEOMICS MARKET SNAPSHOT 186
TABLE 123 APAC: PROTEOMICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 187
TABLE 124 APAC: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 187
TABLE 125 APAC: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 187
TABLE 126 APAC: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 188
11.4.1 CHINA 188
11.4.1.1 China is the fastest-growing market for proteomics 188
TABLE 127 CHINA: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 189
TABLE 128 CHINA: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 189
TABLE 129 CHINA: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 189
11.4.2 JAPAN 190
11.4.2.1 Large number of research initiatives towards the development of precision medicine is driving market growth 190
TABLE 130 JAPAN: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 190
TABLE 131 JAPAN: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 191
TABLE 132 JAPAN: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 191
11.4.3 INDIA 191
11.4.3.1 Large number of proteomics and genomics research studies undertaken in the country to support market growth 191
TABLE 133 INDIA: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 192
TABLE 134 INDIA: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 192
TABLE 135 INDIA: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 193
11.4.4 AUSTRALIA 193
11.4.4.1 Increasing focus of the healthcare system on precision medicine to offer significant growth opportunities 193
TABLE 136 AUSTRALIA: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 194
TABLE 137 AUSTRALIA: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 194
TABLE 138 AUSTRALIA: PROTEOMICS MARKET, BY END USER,
2019–2026 (USD MILLION) 194
11.4.5 REST OF ASIA PACIFIC 195
TABLE 139 ROAPAC: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 195
TABLE 140 ROAPAC: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 196
TABLE 141 ROAPAC: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 196

11.5 LATIN AMERICA 196
TABLE 142 LATIN AMERICA: PROTEOMICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 197
TABLE 143 LATIN AMERICA: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 197
TABLE 144 LATIN AMERICA: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 197
TABLE 145 LATIN AMERICA: PROTEOMICS MARKET, BY END USER,
2019–2026 (USD MILLION) 198
11.5.1 BRAZIL 198
11.5.1.1 Growing contract research and manufacturing activities in the country to support market growth 198
TABLE 146 BRAZIL: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 199
TABLE 147 BRAZIL: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 199
TABLE 148 BRAZIL: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 199
11.5.2 MEXICO 200
11.5.2.1 Strong pharmaceutical industry in the country to provide significant growth opportunities 200
TABLE 149 MEXICO: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 200
TABLE 150 MEXICO: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 200
TABLE 151 MEXICO: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 201
11.5.3 REST OF LATIN AMERICA 201
TABLE 152 ROLATAM: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 201
TABLE 153 ROLATAM: PROTEOMICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 201
TABLE 154 ROLATAM: PROTEOMICS MARKET, BY END USER,
2019–2026 (USD MILLION) 202
11.6 MIDDLE EAST & AFRICA 202
11.6.1 INCREASING PARTNERSHIPS AMONG GLOBAL PLAYERS WITH GOVERNMENT ORGANIZATIONS IN THE REGION TO SUPPORT MARKET GROWTH 202
TABLE 155 MEA: PROTEOMICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 203
TABLE 156 MEA: PROTEOMICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 203
TABLE 157 MEA: PROTEOMICS MARKET, BY END USER, 2019–2026 (USD MILLION) 203
12 COMPETITIVE LANDSCAPE 204
12.1 OVERVIEW 204
FIGURE 29 KEY DEVELOPMENTS IN THE PROTEOMICS MARKET, JANUARY 2018–JANUARY 2021 204
12.2 MARKET SHARE ANALYSIS 205
FIGURE 30 PROTEOMICS MARKET SHARE, BY KEY PLAYER, 2019 205

12.3 COMPANY EVALUATION QUADRANT 205
12.3.1 DEFINITION AND METHODOLOGY 205
12.3.2 VENDOR DIVE OVERVIEW 205
12.3.2.1 Stars 205
12.3.2.2 Emerging leaders 206
12.3.2.3 Pervasive players 206
12.3.2.4 Participants 206
FIGURE 31 PROTEOMICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2019) 206
12.4 COMPANY EVALUATION MATRIX FOR STARTUPS (2019) 207
12.4.1 PROGRESSIVE COMPANIES 207
12.4.2 RESPONSIVE COMPANIES 207
12.4.3 STARTING BLOCKS 207
12.4.4 DYNAMIC COMPANIES 207
FIGURE 32 PROTEOMICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS, 2019 208
12.5 COMPETITIVE SCENARIO 209
FIGURE 33 MARKET EVALUATION FRAMEWORK, JANUARY 2018– JANUARY 2021 209
12.5.1 PRODUCT LAUNCHES 209
TABLE 158 PRODUCT LAUNCHES, JANUARY 2018–JANUARY 2021 209
12.5.2 EXPANSIONS 210
TABLE 159 EXPANSIONS, JANUARY 2018–JANUARY 2021 210
12.5.3 ACQUISITIONS 210
TABLE 160 ACQUISITIONS, JANUARY 2018–JANUARY 2021 210
12.5.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 211
TABLE 161 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, JANUARY 2018–JANUARY 2021 211
13 COMPANY PROFILES 213
(Business overview, Products offered, Recent developments, MNM view)*
13.1 KEY PLAYERS 213
13.1.1 THERMO FISHER SCIENTIFIC, INC. 213
FIGURE 34 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019) 213
13.1.2 AGILENT TECHNOLOGIES, INC. 218
FIGURE 35 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019) 218
13.1.3 MERCK KGAA 222
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2019) 222
13.1.4 DANAHER CORPORATION 230
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 230
13.1.5 WATERS CORPORATION 234
FIGURE 38 WATERS CORPORATION: COMPANY SNAPSHOT (2019) 234
13.1.6 BIO-RAD LABORATORIES, INC. 238
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2019) 238
13.1.7 BRUKER CORPORATION 244
FIGURE 40 BRUKER CORPORATION: COMPANY SNAPSHOT (2019) 244
13.1.8 GE HEALTHCARE 248
FIGURE 41 GE HEALTHCARE: COMPANY SNAPSHOT (2019) 248
13.1.9 PERKINELMER, INC. 252
FIGURE 42 PERKINELMER: COMPANY SNAPSHOT (2019) 252
13.1.10 LUMINEX CORPORATION 255
FIGURE 43 LUMINEX CORPORATION: COMPANY SNAPSHOT (2019) 255
13.1.11 EUROFINS SCIENTIFIC 257
FIGURE 44 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2019) 257
13.1.12 HORIBA, LTD. 260
FIGURE 45 HORIBA, LTD.: COMPANY SNAPSHOT (2019) 260
13.1.13 ILLUMINA, INC. 262
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2019) 262
13.1.14 QIAGEN N.V. 264
FIGURE 47 QIAGEN N.V.: COMPANY SNAPSHOT (2019) 264
13.2 OTHER PLAYERS 267
13.2.1 CREATIVE PROTEOMICS 267
13.2.2 PROMEGA CORPORATION 269
13.2.3 SENGENICS 271
13.2.4 BIOMAX INFORMATICS AG 273
13.2.5 MS BIOWORKS, LLC 274
13.2.6 WUXI NEXTCODE 275
13.2.7 FIOS GENOMICS, LTD. 276
13.2.8 GENEWIZ 276
13.2.9 BIOGNOSYS AG 277
13.2.10 BIOPROXIMITY 278
13.2.11 MRM PROTEOMICS INC. 279
13.2.12 INTEGRATED PROTEOMICS APPLICATIONS 280
13.2.13 POOCHON SCIENTIFIC LLC 281
13.2.14 PROTEOME FACTORY AG 282
13.2.15 VPROTEOMICS 283
13.2.16 APPLIED BIOMICS INC. 284
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 285
14.1 INSIGHTS OF INDUSTRY EXPERTS 285
14.2 ADDITIONAL INSIGHTS 286
14.2.1 MASS SPECTROMETRY 286
14.2.2 QUANTITATIVE PROTEOMICS 287
14.2.3 TARGETED PROTEOMICS 288

14.3 DISCUSSION GUIDE 289
14.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 293
14.5 AVAILABLE CUSTOMIZATIONS 295
14.6 RELATED REPORTS 295
14.7 AUTHOR DETAILS 296



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のプロテオミクス市場予測(~2026年):製品別(分光法、クロマトグラフィー、電気泳動、X線結晶構造解析)、試薬別、サービス別(コアプロテオミクス、バイオインフォマティクス)、用途別(診断、創薬)、エンドユーザー別(病院、ラボ、バイオ医薬品)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆